At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 423 enrolled
Drug / intervention
MVA-BN-Filo +2 morebiological
Likely dose
MVA-BN-Filo 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in Europe
In Brief
A Phase 2 clinical trial evaluating MVA-BN-Filo, Ad26.ZEBOV, and 1 other intervention for Ebola Viral Disease. Completed, enrolled 423 participants across 11 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of 3 vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEbola Viral Disease
CountriesFrance, United Kingdom
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJun 2015
Primary CompletionJan 2018
TodayJul 2026
First PostedApr 15, 2015
Enrollment StartJun 15, 2015
Primary CompletionJan 19, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.2 years ago
Interventions
MVA-BN-Filobiological
One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit \[Inf. U.\] on Day 29, 57, or 85.
Ad26.ZEBOVbiological
One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
Placebobiological
One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.